$1.91
0[0.00%]
Last update: 4:00PM (Delayed 15-Minutes)
Get Real Time Here
Get Real Time Here
$2.04
0.1300[6.81%]
| Open- | Close- |
| Vol / Avg.0 / 1.088M | Mkt Cap93.955M |
| Day Range- - - | 52 Wk Range1.910 - 10.420 |
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%
C4 Therapeutics Stock (NASDAQ:CCCC), Key Statistics
C4 Therapeutics Stock (NASDAQ: CCCC) analysis, key statistics.
Valuation Measures
Enterprise Value
-89.6M
Trailing P/E
- -
Forward P/E
- -
PE Ratio (TTM)
- -
PEG Ratio (TTM)
- -
Price / Sales (ttm)
5.84
Price / Book (mrq)
0.4
Price / EBITDA
- -
Enterprise Value / EBITDA (TTM)
- -
Earnings Yield
-149.21%
Price change 1 M
- -
Stock Price History
Alpha
- -
Beta
- -
Balance Sheet
Book Value per share
4.75
Tangible Book value per share
4.75
Total Liabilities (Quarterly)
141.3M
Total Assets
375M
Total Liabilities
141.3M
Profitability
Net income Growth
- -
Gross Margin
- -
Net Margin
-1348.42%
EBIT Margin
-1325.9%
EBITDA Margin
-1308.71%
Operating Margin
-1410.21%